Stockwinners Market Radar for March 27, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:49 EDT Cathie Wood's ARK Investment bought 54K shares of Kratos Defense today

20:44 EDT Summit Therapeutics CEO buys $411K in common stock - In a regulatory filing, Summit Therapeutics disclosed that its CEO Mahkam Zanganeh bought 110K shares of common stock on March 27th in a total transaction size of $411K.

19:34 EDT SLB to acquire majority ownership in Aker Carbon Capture for NOK4.12B - SLB "announced an agreement to combine its carbon capture business with Aker Carbon Capture to support accelerated industrial decarbonization at scale. Bringing together complementary technology portfolios, leading process design expertise and an established project delivery platform, the combination will leverage ACC's commercial carbon capture product offering and SLB's new technology developments and industrialization capability. It will create a vehicle for accelerating the introduction of disruptive early-stage technology into the global market on a commercial, proven platform. Following the transaction, SLB will own 80% of the combined business and ACC will own 20%. The International Energy Agency (IEA) sees carbon capture, utilization, and sequestration playing a critical role in the net-zero transition-estimating that over one gigaton of CO2 per year will need to be captured by 2030, scaling up to over six gigatons by 2050. SLB will pay NOK 4.12 billion to purchase 80% of Aker Carbon Capture Holding AS, which holds the business of ACC, and will contribute the SLB carbon capture business to the combined entity. SLB may also make additional payments of up to NOK 1.36 billion over the next three years based on the performance of the business. The transaction is subject to regulatory approvals and is expected to close by the end of the second quarter, 2024."

18:41 EDT Broadcom exec sells $6.72M in common stock - In a regulatory filing, Broadcom disclosed that its Semi Solutions president Charlie Kawwas sold 5K shares of common stock on March 25th in a total transaction size of $6.72M.

18:36 EDT Reddit CFO sells $2.32M in common stock - In a regulatory filing, Reddit disclosed that its CFO Andrew Vollero sold 71.8K shares of common stock on March 25th in a total transaction size of $2.32M.

18:34 EDT Reddit COO sells $16.6M in common stock - In a regulatory filing, Reddit disclosed that its COO Jennifer Wong sold 514K shares of common stock on March 25th in a total transaction size of $16.6M.

18:32 EDT Domo expands integration capabilities with Snowflake - Domo (DOMO) "announced at Domopalooza: the AI + Data Conference the expansion of its partnership with Snowflake (SNOW), including the launch of Domo's award-winning Magic ETL capabilities on the Snowflake Data Cloud. Domo, leveraging Snowflake, enables users to simplify data management and access actionable intelligence through a native, bi-directional integration built on Domo Cloud Amplifier. Cloud Amplifier helps joint customers unlock the value of the Data Cloud through a single virtual layer, enabling them to make the most of their existing data and reporting investments by connecting more data, unifying data governance and making real-time insights available and, most importantly, actionable."

18:04 EDT CleanSpark chairman sells $8.47M in common stock - In a regulatory filing, CleanSpark disclosed that its chairman Matthew Schultz sold 367K shares of common stock on March 27th in a total transaction size of $8.47M.

17:58 EDT Ellington Financial reports estimated book value per share $13.66 on Feb. 29 - Ellington Financial announced its estimated book value per share of common stock of $13.66 as of February 29. This estimate includes the effect of the previously announced monthly dividend of 15c per share of common stock, payable on March 25 to holders of record on February 29, with an ex-dividend date of February 28.

17:39 EDT Chemours management determined internal controls over financials 'not effective' - In its 10-K filing, the company stated: "Management has assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2023 using the criteria set forth in the Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management completed an evaluation of our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to the material weaknesses described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We did not design and maintain an effective control environment as senior management failed to set an appropriate tone at the top resulting in a material weakness. Specifically, among other things, there was a lack of transparency with the Company's board of directors by former senior management regarding efforts to delay payments to certain vendors and to accelerate the collection of receivables, and that these individuals engaged in these efforts in part to meet free cash flow targets that the Company had communicated publicly, and which also would be a part of a key metric for determining incentive compensation applicable to both executive officers and to employees. As a result, it was concluded that former senior management violated the Company's "Code of Ethics applicable to the Chief Executive Officer, the Chief Financial Officer, and the Controller". The ineffective control environment contributed to the following additional material weaknesses. We did not design and maintain effective controls related to the information and communication component of the COSO Framework, and principles of internally communicating information, including objectives and responsibilities for internal control, necessary to support the functioning of internal control. Specifically, the Company did not design and maintain effective controls to ensure appropriate communication between certain functions within the Company, including (i) the identification and communication of certain contractual arrangements and (ii) communication of business developments which impact key assumptions used in the goodwill impairment assessment. This material weakness related to information and communication contributed to an additional material weakness in that we did not design and maintain effective controls regarding the evaluation and escalation of reports made through the Chemours Ethics Hotline, including controls regarding the escalation of certain reports to the General Counsel and Chair of the Audit Committee. Additionally, we did not design and maintain effective controls to prevent or timely detect unauthorized changes to our ven dor master files in order to prevent unauthorized cash disbursements. These material weaknesses did not result in any material misstatements of the Company's financial statements or disclosures but did result in immaterial revisions to our March 31, 2023, June 30, 2023 and September 30, 2023 financial statements and a revision to the Company's Balance Sheet as of December 31, 2022 and the Company's Statement of Cash Flows for each of the years ended December 31, 2022 and 2021. Additionally, the material weaknesses described above could lead to a misstatement of substantially all account balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected."

17:34 EDT Lockheed Martin awarded $439.89M Navy contract modification - Lockheed Martin was awarded a $439.89M firm-fixed-price modification to a previously awarded cost-plus-fixed-fee, cost-plus-incentive-fee, firm-fixed-price, and fixed-price-incentive-fee, indefinite-delivery/indefinite-quantity contract. This modification exercises options to provide support equipment, pilot flight equipment, and post ejection survival training material, as well as associated administrative, contract management, planning and readiness reviews and non-recurring introduction to service support in support of site activation and initial sustainment activities for the F-35A, F-35B and F-35C aircraft for the Air Force, Marine Corps, Navy, non-Department of Defense participants, and Foreign Military Sales customers. Work is expected to be completed in December 2029. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. Naval Air Systems Command is the contracting activity.

17:27 EDT Fox Factory to replace E.W. Scripps in S&P 600 at open on 4/3

17:24 EDT VF Corp. to replace ModivCare in S&P 600 at open on 4/3

17:22 EDT Solventum to replace VF Corp. in S&P 500 at open on 4/1 - Solventum (SOLV) will be added to the S&P 500 effective prior to the open of trading on Monday, April 1, replacing V.F. Corp. (VFC), which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 3.

17:10 EDT B. Riley Financial secures extension under existing credit agreement - In a regulatory filing, the company states: "In light of the delayed filing of B. Riley Financial Annual Report on Form 10-K for the year ending December 31, 2023, the Company has secured an extension under its existing credit agreement with Nomura Corporate Funding Americas, LLC of the time required to deliver its 2023 audited financial statements to the administrative agent. While the Company does not believe it will require the full period, the lenders have agreed that the audited financials need not be delivered until April 29, 2024. The Company did not incur any additional fees as a result of the extension. The Company acknowledges the key role its lenders and other counterparties have played in its growth and success and, as evidenced by the extension, continues to maintain an ongoing and productive dialogue with its lenders even through this temporary delay."

16:35 EDT Weibo drops 4% to $9.09 after Goldman downgrade to Neutral

16:31 EDT United Parks & Resorts announces $500M share repurchase program - United Parks & Resorts reported that on March 25, its stockholders overwhelmingly approved a $500M buyback authorization and the amendment of the stockholders agreement with Hill Path Capital LP.

16:28 EDT Avalo Therapeutics up 227% afterhours at $15.60 after announcing AlmataBio deal

16:24 EDT MillerKnoll falls 13% to $26.50 after Q4/FY24 guidance misses estimates

16:15 EDT RH up 4% at $308.00 after Q4 results, above-consensus FY24 guidance

16:14 EDT Carlyle COO Christopher Finn to retire, Lindsay LoBue to succeed as COO - The Carlyle Group announced that Christopher Finn, Chief Operating Officer, will retire from his role as Chief Operating Officer and cease serving as an executive officer effective June 30. Commencing July 1, Finn will become a Senior Advisor to the company. Lindsay LoBue, Deputy Chief Operating Officer, will become Chief Operating Officer, effective July 1. "She is based in New York and is a member of Carlyle's Leadership and Operating Committees. Ms. LoBue joined Carlyle in October 2023 and has served as Deputy Chief Operating Officer since February 2024. Prior to that, Ms. LoBue spent over 20 years at Goldman Sachs, most recently as an Advisory Director working across global divisions on strategic growth initiatives," the company noted in a regulatory filing.

16:10 EDT Franklin Covey sees FY24 adjusted EBITDA at lower end of $54.5M-$58M range - Based on the strength of the Company's business model that features high recurring revenue, high gross margins, and low capital intensity, combined with the continued strength and strategic durability of the All Access Pass and Leader in Me membership subscriptions, the Company looks forward to a strong second half of fiscal 2024. Despite the challenges from the first half of fiscal 2024, the Company expects that its Adjusted EBITDA for fiscal 2024 will be at the lower end of its previously announced guidance range of $54.5 million to $58.0 million in constant currency, which represents 13% growth over the $48.1 million of Adjusted EBITDA achieved in fiscal 2023. The Company expects to achieve this growth despite an uncertain economic environment and while continuing to make additional growth investments. The Company is also confident in the strength of its subscription offerings, which have driven Franklin Covey's growth across recent years, and which are expected to deliver in fiscal 2024 the highest levels of revenue, Adjusted EBITDA, and Free Cash Flow since the sale of the Company's consumer products division.

15:31 EDT Sinclair Broadcast names David Gibber as Chief Legal Officer - Sinclair announced David Gibber has been elevated to Executive Vice President and Chief Legal Officer. Gibber was most recently the company's Senior Vice President/General Counsel, a position he has held since 2019. Gibber joined Sinclair in 2011 and has held several leadership roles including Vice President/Deputy General Counsel, Deputy General Counsel/Director of Legal Services, and Legal Counsel. Gibber also serves on the board of directors of various charitable and community organizations. In this new role, Gibber will continue to oversee the legal, regulatory, distribution and network affiliate functions for the entire company, as well as serve as part of the executive leadership.

14:27 EDT Two trading halted, volatility trading pause

13:34 EDT Mountain Crest Acquisition Corp IV trading resumes

13:25 EDT North American rail traffic up 1.7% for the week ending March 23 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending March 23. AAR also weighed in on the Francis Scott Key Bridge collapse and how railroads are working to limit disruptions. "The top priority following the tragic collapse of the Francis Scott Key Bridge must be supporting the individuals and families impacted," said AAR SVP of Policy and Economics Dr. Rand Ghayad. "At this time, there are many unknowns about the long-term business impacts. However, recent years have shown us the resilience of railroads and the broader logistics sector in adapting swiftly to challenges while continuing to serve our customers. Those lessons will be put to work in the days ahead to minimize disruption to the fullest extent possible." For this week, total U.S. weekly rail traffic was 470,593 carloads and intermodal units, up 2.1% compared with the same week last year. Total carloads for the week ending March 23 were 215,277 carloads, down 6.1% compared with the same week in 2023, while U.S. weekly intermodal volume was 255,316 containers and trailers, up 10.2% compared to 2023. Five of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included grain, up 2,735 carloads, to 21,467; chemicals, up 1,822 carloads, to 33,702; and motor vehicles and parts, up 888 carloads, to 16,109. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 14,169 carloads, to 53,727; nonmetallic minerals, down 2,835 carloads, to 27,607; and metallic ores and metals, down 2,129 carloads, to 18,519. North American rail volume for the week ending March 23, on 10 reporting U.S., Canadian and Mexican railroads totaled 324,001 carloads, down 5.3% compared with the same week last year, and 340,799 intermodal units, up 9.4% compared with last year. Total combined weekly rail traffic in North America was 664,800 carloads and intermodal units, up 1.7%.. North American rail volume for the first 12 weeks of 2024 was 7,798,583 carloads and intermodal units, up 1.8% compared with 2023. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Greenbrier (GBX),Trinity Industries (TRN), FreightCar America (RAIL), Wabtec (WAB) and Rail Vision (RVSN). Reference Link

13:19 EDT Garden Stage Ltd trading halted, volatility trading pause

12:54 EDT Amazon invests additional $2.75B in Anthropic - Amazon stated: "The work Amazon and Anthropic are doing together to bring the most advanced generative artificial intelligence, or generative AI, technologies to customers worldwide is only beginning. As part of a strategic collaborative agreement, we and Anthropic announced that Anthropic is using Amazon Web Services - AWS - as its primary cloud provider for mission critical workloads, including safety research and future foundation model development. Anthropic will use AWS Trainium and Inferentia chips to build, train, and deploy its future models and has made a long-term commitment to provide AWS customers around the world with access to future generations of its foundation models on Amazon Bedrock, AWS's fully managed service that provides secure, easy access to the industry's widest choice of high-performing, fully managed foundation models, along with the most compelling set of features - including best-in-class retrieval augmented generation, guardrails, model evaluation, and AI-powered agents - that help customers build highly-capable, cost-effective, low latency generative AI applications... Deepening our commitment to advancing generative AI, today we have an update on the announcement we made to invest up to $4 billion in Anthropic for a minority ownership position in the company. Last September, we made an initial investment of $1.25 billion. Today, we made our additional $2.75 billion investment, bringing our total investment in Anthropic to $4 billion." Reference Link

12:00 EDT Nuvation Bio rises 30.6% - Nuvation Bio is up 30.6%, or 88c to $3.76.

12:00 EDT GCT Semiconductor rises 217.5% - GCT Semiconductor is up 217.5%, or $14.31 to $20.89.

12:00 EDT X Financial falls -20.1% - X Financial is down -20.1%, or -93c to $3.68.

11:51 EDT Beyond announces partnership with X - Beyond (BYON), the parent company of Overstock, Bed Bath & Beyond, Zulily and a gallery of other brands serving homeowners and renters in America, announced a strategic partnership with X, formerly known as Twitter, to deliver custom short and long form content, develop customer acquisition and retention strategies as well as spotlight the companies' brands on key tent-pole events and holidays. "We are thrilled to be an integrated partner with X as they help us engage more effectively across their 100 million plus U.S. users with both creative content and brand-specific promotional messaging. We recognize the power of the X platform and level of engagement users have with it," said Marcus Lemonis, Executive Chairman of the Beyond board of directors.

11:36 EDT NetEase unveils 'Marvel Rivals' multiplayer game for PC - NetEase (NTES) unveiled a new team-based shooter "Marvel Rivals," a multiplayer game based on Marvel Comics' (DIS) superhero characters. The game is being developed for PC, with an alpha test for the game set to launch in May 2024. Reference Link

10:51 EDT Tsakos Energy trading halted, news pending

10:02 EDT Q2 Holdings promotes Katharine Biggs to CPO - Q2 Holdings announced that Katharine Briggs has been promoted to the newly created role of Chief Product Officer and will become a member of Q2's executive leadership team. This change will take effect on March 31, 2024. In this new role, Briggs will lead the strategic direction and design of Q2's products and solutions to enable banks and credit unions to better onboard, grow and serve their consumer, small business, and corporate account holders. She will report directly to Q2 President Kirk Coleman. Most recently, she led Q2's Customer Success organization, working closely with the Product teams to ensure Q2 solutions deliver measurable value and success to more than 1300 financial institution customers

10:00 EDT X Financial falls -16.9% - X Financial is down -16.9%, or -78c to $3.83.

10:00 EDT Ouster rises 17.1% - Ouster is up 17.1%, or 85c to $5.83.

10:00 EDT GCT Semiconductor rises 47.6% - GCT Semiconductor is up 47.6%, or $3.13 to $9.71.

09:47 EDT Adient: Strong performance partially offsetting softer volume - In slides being presented at the Bank of America Automotive Summit, Adient says stronger business performance is partially offsetting softer than expected volume. Business performance is tracking ahead of schedule, driving earnings improvement, the company says.

09:47 EDT X Financial falls -18.4% - X Financial is down -18.4%, or -85c to $3.76.

09:47 EDT Noah Holdings rises 12.4% - Noah Holdings is up 12.4%, or $1.25 to $11.37.

09:47 EDT GCT Semiconductor rises 84.0% - GCT Semiconductor is up 84.0%, or $5.53 to $12.11.

09:36 EDT NovoCure trading halted, volatility trading pause

09:26 EDT Carnival: Booked position for remainder of FY24 'best on record' - The company experienced an early start to a robust wave season with record booking volumes for all future sailings that exceeded expectations. The company achieved considerably higher prices (in constant currency) than last year on first quarter booking volumes, having entered 2024 with less inventory remaining for sale, in line with the company's strategy to pull the booking curve forward. In fact, pricing (in constant currency) on bookings for the remainder of the year for the company's NAA segment was considerably higher compared to the prior year, with its Europe segment up double digits. "We are enjoying a phenomenal wave season with strength across all major deployments and brands. Even with less inventory available for the remainder of the year, booking volumes hit an all-time high, driven by demand for 2025 sailings and beyond. Our brands have demonstrated continued success creating demand that outstrips available capacity translating into higher prices (in constant currency) and a further elongation in the booking curve," CEO Weinstein noted. The company's booked position for the remainder of the year continues to be the best on record, with both pricing (in constant currency) and occupancy considerably higher than 2023.

09:23 EDT Carnival sees remainder of FY24 CapEx $2.3B - Sees FY25 CapEx $3B; FY26 CapEx $2.4B.

09:19 EDT Carnival: FY24 guidance does not include impact from Francis Scott Key Bridge - The company stated, "Francis Scott Key Bridge in Baltimore: Given the timing of yesterday's event in Baltimore and the temporary change in homeport, our guidance does not include the current estimated impact of up to $10 million on both adjusted EBITDA and adjusted net income for the full year 2024."

09:17 EDT Carmell Therapeutics closes Axolotl Biologix sale transaction - Carmell announced the closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable. Following the sale of AxoBio, Carmell's financial position is expected to improve as follows: $4 million drop in annualized cash burn based on AxoBio's actual January 2024 financials. $15.6 million reduction in debt: $7.6 million of AxoBio subsidiary level debt plus $8 million note payable related to the AxoBio acquisition. $7 million increase in tangible equity due to elimination of AxoBio's negative tangible equity. 29% reduction in EPS dilution due to the cancellation of 8.09 million CTCX common shares on a fully diluted basis. Post-Closing, Carmell has 19.25 million common shares outstanding.

09:15 EDT Syntec Optics secures $2.8M order for opto-mechanical subsystems - Syntec Optics announced $2.8M million in orders for high-precision opto-mechanical components and subsystems used in the production of the latest night vision goggles used by US defense. Delivery is scheduled for 2024. The initial development and early production orders of the latest night vision goggles for the US defense start in 2018. Since then, Syntec Optics, with its low-weight optics, began contributing to the system.

09:12 EDT Revive Therapeutics submits Type C meeting request package to FDA - Revive Therapeutics has submitted a Type C meeting request package to the U.S. Food & Drug Administration for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting. Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA. On July 6, 2023, the Company announced the results of its Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19. Under the Study's primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization, there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group. No hospitalizations occurred in the Bucillamine large dose group. The Company evaluated certain Study endpoints, including the COVID-19 clinical symptoms data. Based on preliminary analyses, the data demonstrated that for patients with oxygen saturation less than96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation. Additional analyses of the Study data may suggest Bucillamine's potential for long COVID. A study titled "Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry" showed that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provided a rationale to test thiol-based drugs such as Bucillamine as novel treatments for COVID-19

09:07 EDT Saputo signs large-scale virtual power purchase agreement with Capital Power - Saputo announced it has entered into a 15-year virtual power purchase agreement, VPPA, with Capital Power, a North American power producer. The long-term commitment, supported by energy procurement advisor Schneider Electric, marks a key milestone in Saputo's sustainability efforts, as it will allow the Company to make significant strides towards its climate target for 2025 and future environmental goals. The agreement pertains to a Canadian-based wind facility currently under construction. Subject to final regulatory approvals and once operational, the portion of the wind facility contracted by Saputo will generate approximately 206,300 MWh of renewable electricity per year, reducing the Company's CO2 emissions by more than 140,000 tonnes - equivalent to taking more than 30,000 cars off the road. The new VPPA will ultimately cut down Saputo's global CO2 footprint by 13 per cent.

09:06 EDT Chegg appoints Deena Bahri CMO effective March 27 - Chegg announced the appointment of Deena Bahri as Chief Marketing Officer, effective March 27 During her 20-year career, Ms. Bahri has held key marketing positions at innovative tech-driven brands including Birchbox, Gilt Groupe, and Reebok. She was most recently Chief Marketing Officer of leading current culture marketplace StockX, where she led the global marketing and merchandising teams. "Deena is a visionary leader with a proven track record of accelerating game-changing brands, and we are so excited to have her on board," said Nathan Schultz, COO of Chegg. "She joins us at the perfect moment, as we embark on the next chapter of dynamic growth and innovation with our personalized learning assistant." Schultz added, "I also want to thank Esther Lem for her passion and dedication over the years. She played a critical role in transforming Chegg from a textbook rental company to the largest publicly traded student-first learning brand. We wish her all the best in her retirement."

09:06 EDT TruGolf announces global franchising with Franchise Well - TruGolf Holdings announced a strategic agreement with Franchise Well to accelerate its global expansion through a regional developer franchise model. This relationship marks a pivotal moment for TruGolf as it harnesses the power of franchising to amplify its global presence and cater to the burgeoning demand for immersive off-course golf experiences. "Our mantra is "Golf Easy" and we view franchising as a critical step towards achieving that vision by making golf experiences significantly more accessible in the U.S. and worldwide," stated Chris Jones, Chief Executive Officer of TruGolf. "TruGolf already boasts a presence in over 30 countries. Franchising serves as a capital-efficient model to drive our growth and fuel global expansion. This relationship with Franchise Well accelerates our growth and allows us to deploy our innovative technology to even more enthusiasts around the world."

09:04 EDT LogicMark reschedules Q4, 2023 financial results release - LogicMark announced that it has rescheduled the release of fourth quarter and full year 2023 financial results, originally scheduled for March 27, 2024. LogicMark now expects to release results before the market opens on Monday, April 1, 2024. The conference call will be held the same day at 1:30 p.m. PDT / 4:30 p.m. EDT, hosted by Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO.

09:04 EDT NexGel reschedules Q4, 2023 results conference call - NEXGEL announced rescheduling its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET. The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.

09:03 EDT OpenText, X12 renew commercial use partner license agreement - OpenText and X12 announced the renewal of their commercial use partner license agreement. This long-standing collaboration underscores OpenText's commitment to and support for X12 standards across its expansive supply chain network.

09:01 EDT Ansys announces new OEM partnership with SynMatrix - Ansys announced a new OEM partnership with SynMatrix to streamline RF filter design workflows for wireless communications applications. SynMatrix develops industry-leading RF filter design and optimization tools that integrate with HFSS electromagnetic simulation. Available through Ansys, SynMatrix software enables accelerated development, helps reduce project risk, and fosters the design exploration of new filter technologies. The SynMatrix partnership simplifies the workflow and reduces the number of software tools throughout the entire development cycle.

08:57 EDT Getty Images, United Football League renew photography partnership - Getty Images has been named the Official Photographic Agency of the United Football League. The UFL season kicks off on Saturday, March 30, 2024, when the Birmingham Stallions visit the Arlington Renegades at 1 PM ET. As part of the multi-year agreement, Getty Images' award-winning sports photographers and editors will deliver high-quality imagery from every game during the 12-week season. This includes all on and off the field action, such as gameplay, warmups, fan interactions, celebrations and more, all to be distributed exclusively through gettyimages.com.

08:51 EDT Mawson Infrastructure expands co-location business - Mawson Infrastructure Group has expanded its co-location business. On March 25, 2024, Mawson signed a customer service addendum to its previous Customer Service Framework Agreement with Consensus Technology Group that expanded its co-location services business by approximately an additional 5,880 miners or approximately an additional 20 MW. The initial Customer Agreement signed on October 12, 2023, between wholly owned subsidiaries of Mawson and Consensus, for co-location business services was approximately 15,876 miners or approximately 50 MW. With the execution of this new customer service addendum, Mawson is expected to provide Consensus co-location business services for a total of approximately 21,756 miners or approximately 70 MW, with Mawson's total co-location services business growing to about 25,284 miners or about 82 MW upon full deployment. In addition to its co-location services business, Mawson operates self-mining bitcoin and energy management businesses.

08:50 EDT Marinus Comments on patent challenge by Ovid Therapeutics - Marinus Pharmaceuticals (MRNS) "affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review, IPR, challenge of U.S. Patent 11,110,100 from Ovid Therapeutics (OVID). filed on March 26. This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus SE and refractory status epilepticus RSE. Marinus has multiple patents relating to ganaxolone for the treatment of SE and RSE. "Over the past two decades, Marinus has invested more than $100M into our ganaxolone development programs in SE," stated Dr. Scott Braunstein, Chairman and CEO of Marinus. "That investment has yielded a strong patent portfolio, fortified by robust clinical data on the pharmacology and effective dosing of ganaxolone, and underscores our commitment to improving the lives of patients and families affected by seizure disorders. We believe this Ovid challenge is without merit and is an unfortunate distraction to the important work we do at Marinus. As a company grounded in scientific research, we will vigorously defend our patents which support our mission of delivering innovative new treatment options to patients with significant unmet needs."

08:44 EDT Ondas' American Robotics partners with ResilienX - Ondas Holdings' American Robotics is entering a strategic partnership with ResilienX. This collaboration advances the safety and reliability of autonomous systems, particularly those deployed for Beyond Visual Line of Sight applications, and in intricate operational environments. Through this strategic alliance, American Robotics will integrate ResilienX's IASMS solution, known as FRAIHMWORK, which is pivotal for monitoring the health, integrity, and performance of associated elements for BVLOS ecosystems, and within fully autonomous solutions, including the American Robotics Optimus System. Additionally, American Robotics will begin to resell ResilienX's software solutions.

08:42 EDT Li Auto announces Put Right notification for convertible senior notes - Li Auto is notifying holders of its 0.25% Convertible Senior Notes due 2028 that pursuant to the Indenture dated as of April 12, 2021 relating to the Notes by and between the Company and Deutsche Bank Trust Company Americas, as trustee and paying agent, each holder has the right, at the option of such holder, to require the Company to purchase all of such holder's Notes or any portion of the principal thereof that is equal to US$1,000 principal amount for cash on May 1, 2024. The Put Right expires at 5:00 p.m., New York City time, on Monday, April 29, 2024. As required by rules of the United States Securities and Exchange Commission, the Company will file a Tender Offer Statement on Schedule TO today. In addition, documents specifying the terms, conditions, and procedures for exercising the Put Right will be available through the Depository Trust Company and the paying agent, which is Deutsche Bank Trust Company Americas. None of the Company, its board of directors, or its executive management has made or is making any representation or recommendation to any holder as to whether to exercise or refrain from exercising the Put Right.

08:40 EDT One Stop Systems to design, manufacture new video concentrator - One Stop Systems announced a new purchase order from the U.S. Army to design and manufacture a video concentrator. This new video concentrator will be incorporated into the rugged 360-degree visualization compute system that OSS is designing and building for U.S. Army land vehicles, including the Stryker, Bradley and Abrams. This new order expands the company's scope on the visualization system that OSS originally announced in February 2023.

08:39 EDT SRIVARU announces completed on-road driving tests of Prana 2.0 - SRIVARU announced it has successfully completed on-road driving range tests of the Company's new Prana 2.0 intelligent battery system. The Prana 2.0 intelligent battery system exceeded initial performance expectations when installed in the Prana Grand and Prana Elite models, achieving an extended vehicle range in excess of 150 kilometers for the Prana Grand and 250 kilometers for the Prana Elite, both on a single charge. Mohanraj Ramasamy, CEO of SRIVARU, stated, "We continue to be a leader in the market in terms of quality and innovation, bringing high-performance and sustainable alternatives to meet the growing demand for premium two-wheel electric motorcycles. Having just completed our on-road driving* range tests, we are extremely pleased with the impressive driving range of the Prana 2.0. Prana 2.0 achieved a range well in excess of typical electric motorcycles and surpassed our own internal targets. Previously, the Prana Grand had an expected range of 126 km for standard road driving. With the Prana 2.0 intelligent battery system, we have increased the expected range for standard road driving by over 20%, allowing us to achieve an expected range well in excess of 150 km for Prana Grand. The Prana Elite's expected range for standard road driving has now surpassed 250 kilometers on a single charge, setting a new benchmark for the industry. We have also incorporated other enhancements, such as temperature sensors in the battery pack, which allow for audio and visual battery temperature warnings before degradation or potential fires. The new and enhanced Prana 2.0 intelligent battery system is also designed to meet the newest safety standard of AIS-156 Phase 3 certification. Overall, we believe the combination of our industry-leading technology and performance, along with the attractive price point of our electric motorcycles, positions us to become a leader in the market-not only in India but around the world."

08:38 EDT Foremost Lithium provides drilling progress update at Zoro Lithium Property - Foremost Lithium Resource & Technology provides a drilling progress update at the Zoro Lithium Property located in the Snow Lake region of Manitoba. Foremost reports the widest drill intercept to date with an intersection of spodumene-bearing pegmatite at Dyke 1, spanning a cumulative length of 32.53 meters. Dyke 1 hosts the Company's maiden inferred resource of 1,074,567 tons at a grade of 0.91% Li2O, with a cut-off of 0.3%, as outlined in the Company's filed Regulation SK-1300 Technical Report Summary and NI-43-101 Technical Report. Drill holes FL-24-009 and FL24-010 intersected 32.53 metres and 14.5 metres of spodumene-bearing pegmatite, respectively.

08:36 EDT LM Funding regains compliance with Nasdaq continued listing requirement - LM Funding America announced that the Company received notice from Nasdaq on March 26, 2024, indicating that LM Funding had regained compliance with the minimum bid price requirement under Nasdaq Rule 5550(a)(2). Bruce Rodgers, Chairman and CEO of LM Funding, commented, "We are pleased to have regained compliance with the continued listing requirements of Nasdaq. The preservation of our Nasdaq listing is paramount to the Company, given the credibility and exposure it offers. As our business progresses and gains momentum, we believe our listing is vital to our mission of enhancing shareholder value and strategically aligning the Company for ongoing success."

08:34 EDT Lixte Biotechnology announces publication on LB-100 in cancer cells - LIXTE Biotechnology announced publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled "Paradoxical activation of oncogenic signaling as a cancer treatment strategy." The finding opens a potentially new treatment strategy in addition to LIXTE's current three clinical trials. As will be published in the July 2024 issue and posted online today, LB-100 was shown to trigger hyper-activation of the signals that are responsible for the deregulated proliferation of cancer cells, which is the opposite of most of the current generation of cancer therapies. The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase. This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture. Resistance to therapy is the leading cause of death due to cancer. Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant. Specifically, colon cancer cells that developed resistance to LB-100 had lost many of the features that make the cells cancerous in the first place and were unable to form tumors in experimental animal models. This "tumor suppressive drug resistance" stems from the unique features of LB-100. Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous.

08:29 EDT Pieris Pharmaceuticals sees cash runway into 2027 - As previously disclosed, the Company remains eligible to receive contingent milestone and royalty payments across its partnered 4-1BB bispecific Mabcalin protein franchise resulting from its partnerships with Pfizer, Boston Pharmaceuticals, and Servier. More specifically: All partnered programs are fully funded by the respective partner, and there are no further discovery or development obligations for the Company; The Company may be entitled to aggregate milestones of up to $20 million upon first patient dosed in the phase 2 trials for SGN-BB228, S095012 and BOS-342, which are all currently in phase 1 clinical development; The Company may be entitled to aggregate milestones of up to $55 million upon first patient dosed in pivotal clinical trials for SGN-BB228, S095012 and BOS-342; Two additional discovery programs with Pfizer that would entitle the company to additional milestones if brought forward into IND-enabling activities; Total development milestone potential from the three clinical stage assets in single, primary indications could be up to $275 million. Total commercial milestone potential on the same assets, if they are approved, could amount to more than $500 million. A potential additional aggregate amount of up to $160 million in both developmental and commercial milestones exists if these programs are developed in additional indications; and In addition to the milestone potential, all programs are eligible for royalties from commercial sales ranging from mid-single digits to low double digits. In addition to alliance management activities for the partnered programs above, the Company remains committed to trying to obtain value for its products in prior development, including cinrebafusp alfa, as well as proprietary platform capabilities by pursuing potential out-licensing or sale transactions. In addition to pursuing possible monetization of the projected royalty and milestone payments at attractive valuations, the Company may also, from time-to-time, opportunistically consider other options that it believes may increase stockholder value. As of December 31, 2023, the Company had $26.4 million in cash and investments. The Company does not expect to have any future financing requirements to achieve the near-term milestone potential of its partnered programs. The Company may consider cash dividends as and when milestone or other payments are received if the Company determines there is sufficient cash and investments to achieve the Company's near and long-term objectives.

08:23 EDT FSD Pharma partners with iNGENu CRO to conduct Lucid-21-302 study - FSD Pharma announced that through its subsidiary, HUGE Biopharma Australia, it entered into agreement with iNGENu CRO on March 26, 2024 to conduct "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants". Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis. It is a patented New Chemical Entity that has shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. In a prior Phase 1 single ascending dose study, Lucid-21-302 was shown to be safe and well-tolerated in the dose range of 50-300 mg p.o. administered once to healthy adults, with no difference in pharmacokinetics between the fed and fasted states.

08:21 EDT Avicanna announces Canadian launch of 10% CBD proprietary formula - Avicanna announces the launch of RHO Phyto Micro Drop 100, a 10% CBD, proprietary oral formulation in Canada. RHO Phyto Micro Drop 100, is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology. RHO Phyto Micro Drop 100 will be available to Canadian patients with medical authorization exclusively at the MyMedi.ca medical cannabis care platform.

08:20 EDT SaverOne 2014 signs milestone OEM agreement with IVECO - SaverOne 2014 announced that it has signed an OEM agreement with IVECO, the brand of Iveco Group N.V. that designs, manufactures and markets light, medium and heavy commercial vehicles. The agreement seals the collaboration to develop a solution to prevent driver distraction from cellphone use. The OEM agreement covers the integration of SaverOne's safety technology within IVECO's vehicles through their manufacturing line. Initially, throughout 2024, SaverOne's software will be integrated within IVECO's hardware. Future further evolutions, may include the integration of SaverOne's mobile app with IVECO's mobile app, and SaverOne's hardware and software within IVECO's assembly line. The first IVECO vehicles with the integrated SaverOne software solution are expected to be delivered this year.

08:18 EDT PharmAla announces USPTO allowance for granting of patent for ALA-002 - PharmAla Biotech announces that the US Patent and Trademark Office, USPTO, has indicated it is issuing an allowance for the granting of a patent for ALA-002, the company's lead investigational MDXX Novel Chemical Entity, NCE. This provides the Company a strong basis for ongoing protection of this intellectual property, IP. "MDMA is relatively unique in that it has two enantiomers that are active, but are active in dramatically different ways. In the brain, these two variants of the molecule have a synergistic effect. In short, the sum of these parts is greater than the whole," said Dr. Harpreet Kaur, Vice President of Research at PharmAla Biotech. "Viewed this way, it becomes obvious that the effects of racemic MDMA should be viewed not as one active, but as a combination effect - and as such, it is open to optimization. With ALA-002, we believe we have done that difficult work, and have created an improved, novel, next generation MDMA drug substance formulation."

08:15 EDT MiMedx provides update on AXIOFILL Request for Designation from FDA - MiMedx Group announced that the U.S. Food and Drug Administration, FDA, has issued a determination letter in connection with the RFD process related to AXIOFILL, a human-derived particulate wound dressing. In the letter, FDA reaffirmed its position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act, PHSA. Joseph Capper, MIMEDX Chief Executive Officer, commented: "We are disappointed that the FDA, through the RFD process, has reached a conclusion that continues an inconsistent approach to regulating AXIOFILL and other human-derived particulate products. As I stated on our February conference call, we intend to exhaust all of our legal and regulatory options in an attempt to ensure continued access to this incredibly safe and effective product. Since the FDA has issued a final agency decision, we are taking steps to assert our position in court."

08:13 EDT Aligos presents data at APASL 2024 from ALG-055009, ALG-000184 studies - Aligos Therapeutics announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver, APASL, 2024, being held March 27-31, 2024 in Kyoto, Japan. The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin, an indicator of target engagement in the liver. "We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024. After the recent initiation of our Phase 2a HERALD study of ALG-055009 in MASH subjects, we remain encouraged by the data presented showing a favorable safety profile and strong evidence of target engagement, as shown by induction of sex hormone binding globulin and lowering of atherogenic lipids. We continue to believe our molecule has the potential to be best-in-class," said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. "In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers. These promising results affirm our belief that this compound will play an essential role in the future treatment of hepatitis B."

08:11 EDT Immuneering announces first patient dosed in Phase 1/2 trial of IMM-6-415 - Immuneering announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations. During the 2023 AACR-NCI-EORTC conference, Immuneering presented data showing that IMM-6-415 in combination with encorafenib achieved greater tumor growth inhibition and improved durability when compared head-to-head with binimetinib plus encorafenib, in animal models of RAF mutant melanoma and colorectal cancer, consistent with the thesis that DCI can outperform chronic MAPK inhibition. "We are pleased to have dosed the first patient in our Phase 1/2a trial for IMM-6-415, our second product candidate to enter the clinic," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "IMM-6-415 is designed to deprive malignant cells of the continuous MAPK signaling they need by strongly inhibiting the pathway twice per day, while also providing healthy cells with MAPK signaling twice per day through near-zero drug troughs. We believe the shorter half-life of IMM-6-415 could provide a potential treatment option for a broad patient population with RAS or RAF mutations. We look forward to sharing initial PK/PD and safety data from the Phase 1 portion of our Phase 1/2a trial in 2024."

08:10 EDT 89bio receives EMA PRIME status for Pegozafermin - 89bio announced that the European Medicines Agency has granted Priority Medicines status to pegozafermin in patients with MASH. The PRIME status was supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin in patients with non-cirrhotic MASH with fibrosis (F2-F3) and MASH with compensated cirrhosis. "The EMA PRIME status further supports pegozafermin's positioning as a leading FGF21 analog for the treatment of MASH, which has demonstrated robust anti-fibrotic and metabolic benefits as seen in our Phase 2b ENLIVEN trial," said Rohan Palekar, Chief Executive Officer of 89bio. "This status recognizes the urgent need for effective treatment options for MASH patients with advanced fibrosis and underscores pegozafermin's potential to address the targeted unmet medical need. We look forward to working closely with regulatory agencies as we continue to advance our Phase 3 clinical development program, ENLIGHTEN, aimed at potentially benefiting advanced MASH patients and MASH patients with compensated cirrhosis."

08:10 EDT UnitedHealth's Optum to buy Steward physician group - Senator Edward J. Markey of Massachusetts, chair of the Senate Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security, released a on news that UnitedHealth's Optum Financial is seeking to purchase the physician group of Steward Health Care: "Steward Health Care-which operates nine health care facilities across Massachusetts-is currently facing significant financial insecurity as a result of previously accumulated debt. Steward Health Care was previously owned by Cerberus Capital Management, a private equity company that generated $800M in profit from Steward. After Steward recklessly took on massive debt that is continuing to that put hospitals in Massachusetts and across the country into financial crisis, the Massachusetts health care system must move away from Steward's financial insecurity. With this announcement, Optum must demonstrate that it can meet the even greater responsibility to preserve and protect health care access in the Commonwealth, and I hope they will live up to that responsibility by controlling costs and putting patients and providers first. But a health care system that focuses more on profit motive than patient outcomes needs reform. That is why I am holding a congressional hearing in Boston and have invited Steward CEO Dr. Ralph de la Torre to testify and explain Steward's position. For-profit companies that elect to participate in the health care system must understand that their decisions have direct impacts on communities, and they must and will be held accountable." Reference Link

08:08 EDT Aeterna Zentaris expects cash to fund operations into 2025 - The Company had $34.0 million in cash and cash equivalents at December 31, 2023

08:04 EDT PPG announces appointment of Robert Massy as CHRO - PPG announced the appointment of Robert Massy as senior vice president and chief human resources officer, CHRO , effective March 18. Reporting to Tim Knavish, PPG chairman and chief executive officer, Massy will be responsible for leading the company's global human resources organization. He will be located at PPG's global headquarters in Pittsburgh and serve as a member of the company's Operating Committee. Massy will succeed Kevin Walling, who will retire from PPG on April 1 .

08:01 EDT Medtronic announces FDA approval for Evolut FX+ TAVR - Medtronic announced that the FDA has approved the Evolut FX+ transcatheter aortic valve replacement, or TAVR, system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access. The Evolut FX+ TAVR system offers larger coronary access windows through a modified diamond-shaped frame design, which is four times larger than previous iterations of the Evolut TAVR system. Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies. Additionally, the new design does not compromise the market leading valve performance, excellent hemodynamics, and radial strength that clinicians expect from the Evolut platform. Severe aortic stenosis occurs when the aortic valve leaflets become stiff and thickened and have difficulty opening and closing, making the heart work harder to pump blood to the rest of the body. Severe aortic stenosis often reduces a patient's quality of life and limits their daily activities. If left untreated, 50% of patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years.

07:49 EDT Novocure spikes 30% after drug trial met primary endpoint - Shares of oncology drug maker Novocure spiked over 30% after the company reported that its METIS Phase 3 clinical trial met the primary endpoint in its NSCLC study. Shares of Novocure were up approximately 31% or almost $4 per share to more than $17 in pre-market on Wednesday.

07:42 EDT Sonoma Pharmaceuticals highlights safety advantages of microcyn products - Sonoma Pharmaceuticals highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products. Recently, there have been concerns that popular dermatology products can form benzene, a known carcinogen. A citizen petition by Valisure, LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over-the-counter and prescription dermatology products containing benzoyl peroxide. Testing by Valisure showed that benzoyl peroxide in dermatology products from major brands can form benzene, a known human carcinogen, at unacceptably high levels. Previous testing by Valisure has found unacceptably high levels of benzene in common hand sanitizers, as well as in after-sun products. Sonoma's Microcyn products contain hypochlorous acid, a naturally-occurring compound found in the human body. Our patented Microcyn technology is clinically proven to safely remove microorganisms, without drying the skin or harming healthy tissue. Our products also manage pain and itch from minor skin irritations, lacerations, abrasions and minor burns, including sunburns. Unlike many over-the-counter dermatology products, Sonoma's products are regulated by the FDA as 510(k) medical devices. Sonoma has never used benzoyl peroxide in any of its products. "We understand that consumers are seeking safe and effective products, particularly now when there are so many concerns about dangerous ingredients in dermatology and other topical products," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "For over 20 years, we have developed Microcyn technology products that prioritize the health of patients and at-home users, so that consumers do not have to choose between effectiveness and safe ingredients."

07:40 EDT Alamos Gold to acquire Argonaut Gold for C$0.40 per share - Alamos Gold (AGI) and Argonaut Gold (ARNGF) have entered into a definitive agreement whereby Alamos will acquire all of the issued and outstanding shares of Argonaut pursuant to a court approved plan of arrangement. As part of the Transaction, Alamos will acquire Argonaut's Magino mine, located adjacent to its Island Gold mine in Ontario, Canada. The integration of the two operations is expected to create one of the largest and lowest cost gold mines in Canada. Through the use of shared infrastructure, Alamos expects to unlock significant value with immediate and long-term synergies expected to total approximately $515 million. The addition of Magino is expected to increase Alamos' combined gold production to over 600,000 ounces per year, with longer term production potential of over 900,000 ounces per year. The combination materially enhances Alamos' position as a leading, Canadian focused, intermediate producer, with growing production and declining costs. Concurrently with the Transaction, Argonaut's assets in the United States and Mexico will be spun out to its existing shareholders as a newly created junior gold producer. SpinCo will own the Florida Canyon mine in the United States, as well as the El Castillo Complex, the La Colorada operation, and the Cerro del Gallo project, located in Mexico. Under the terms of the Agreement, each Argonaut common share outstanding will be exchanged for 0.0185 Alamos common shares and 1 share of SpinCo. The Exchange Ratio implies estimated total consideration of C$0.40 per Argonaut common share, or $325 million. This represents a 34% premium based on Argonaut's and Alamos' closing prices on March 26, 2024 on the Toronto Stock Exchange, and a 41% premium based on both companies' 20-day volume-weighted average prices. Total consideration includes C$0.34 of Alamos common shares, based on the closing price of Alamos common shares on the TSX on March 26, 2024, and SpinCo common shares with an estimated value of C$0.063. Alamos expects to issue approximately 20.3 million common shares as part of the Transaction, representing an equity value of approximately $276 million on a fully diluted in-the-money basis, and an enterprise value of $516 million. Upon completion of the Transaction, existing Alamos and Argonaut shareholders will own approximately 95% and 5% of the pro forma company, respectively. In connection with the Transaction, Alamos has agreed to provide Argonaut with a private placement equity financing in the amount of C$50 million priced at an 8% discount to Argonaut's 5-day volume-weighted average share price as of March 26, 2024. This will provide Alamos with a 14% interest in Argonaut on an issued and outstanding basis. This financing will allow Argonaut to fund its immediate liquidity needs related to its loan facilities and operations. The Private Placement Transaction is expected to close in early April 2024. SpinCo SpinCo will own the Florida Canyon mine in the United States, as well as the El Castillo Complex, the La Colorada operation, and the Cerro del Gallo project, located in Mexico. Upon SpinCo going public, Alamos has agreed to subscribe for a further $10 million to obtain a 19.9% interest in SpinCo. Transaction Summary The proposed Transaction will be completed pursuant to a plan of arrangement completed under the Business Corporations Act. The Transaction will require approval by 66 2/3% of the votes cast by the shareholders of Argonaut at a special meeting of Argonaut shareholders expected to be held in June 2024. The directors and members of senior management of Argonaut, as well as Argonaut's two largest shareholders have entered into support agreements pursuant to which they agreed to vote their shares in favor of the proposed Transaction. In addition to shareholder and court approvals, the Transaction is subject to applicable regulatory approvals and the satisfaction of certain other closing conditions customary for a transaction of this nature. The Arrangement Agreement includes customary deal protections, including fiduciary-out provisions, non-solicitation covenants, and the right to match any superior proposals. Additionally, a break fee in an amount of C$20 million is payable to Alamos by Argonaut in certain circumstances, if the Transaction is not completed, and an expense reimbursement fee is payable by Alamos to Argonaut in certain circumstances, if the Transaction is not completed. Full details of the Transaction will be included in the meeting materials which are expected to be mailed to Argonaut shareholders in May 2024.

07:36 EDT Enovix awarded 15-year Pioneer Status from MIDA - Enovix announced it has been granted 15-year Pioneer Status from the Malaysian Investment Development Authority, MIDA, for manufacturing its batteries in Malaysia. Enovix's high-volume manufacturing facility, Fab2, is located in the Penang Science Park in Penang, Malaysia. Enovix previously announced the establishment of Enovix Malaysia in March 2023. "Being awarded Pioneer Status is a monumental milestone for Enovix as we become further established in Malaysia and begin to ramp up manufacturing in our Fab2 facility," said Ajay Marathe, Chief Operating Officer of Enovix Corporation. "This status will improve our net profitability in the long-term as we scale the business and we are thrilled that MIDA has granted us Pioneer Status to support our efforts. We hope our presence will benefit Malaysia, particularly as we continue to grow and offer employment opportunities across R&D and manufacturing."

07:34 EDT PDS Biotechnology to prioritize triple combination in place of VERSATILE-003 - PDS Biotechnology announced an update to its clinical development strategy and reported its financial results for the year ended December 31, 2023. "We have obtained compelling data from several Phase 2 trials in the fourth quarter of 2023, including long-tem survival data from the National Cancer Institute-led triple combination trial of PDS01ADC in combination with Versamune HPV and an investigational immune checkpoint inhibitor, as well as our VERSATILE-002 study," said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. "We now have a better understanding of how our drug platform technology works in advanced cancer, and we have therefore made the strategic, data-driven decision to add our novel, investigational IL-12 fused antibody drug conjugate, PDS01ADC, to the promising combination of Versamune HPV and KEYTRUDA to advance the triple combination as our top clinical development priority. By initially addressing the rapidly growing unmet medical need in recurrent metastatic HPV+ head and neck squamous cell cancer, we strongly believe this approach may rapidly establish our proprietary combination of PDS01ADC and Versamune HPV as a transformative oncology treatment. The data suggest that the triple combination may result in a significant improvement in overall survival rates for patients who currently lack an effective treatment option. It may also significantly increase the rates of durable tumor shrinkage or overall responses. We are grateful to the patients and physicians who participated in the clinical trials which have helped inform our understanding of how the drug therapies may be used most effectively to safely address advanced cancer, and our decision to prioritize the triple combination." With the recent long-term survival Phase 2 data from the NCI-led triple combination trial, together with favorable safety and extended survival results seen in both ICI naive and resistant patients in our VERSATILE-002 trial, PDS Biotech has decided to prioritize the triple combination in place of the VERSATILE-003 trial. This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

07:25 EDT VERB's MARKET.live enters partnership with TikTok - Verb Technology Company has entered into a formal partnership with TikTok Shop pursuant to which MARKET.live has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner. Under the terms of the partnership, TikTok Shop refers consumer brands, retailers, influencers and affiliates leads to Market.live for a menu of paid services that include, among other things, assistance in onboarding to TikTok and establishing a TikTok store, hosting training sessions and webinars for prospective TikTok Shop sellers, studio space rental in both the West Coast and East Coast MARKET.live studios, content creation and production services, and TikTok Shop maintenance, including enhancements to existing TikTok Shop seller stores. The partnership also contemplates TikTok Shop sponsored studio rentals, as well as a paid-for "day pass" for use of MARKET.live studio services by TikTok creators, influencers and affiliates. MARKET.live will generate revenue through fees, including monthly recurring fees, paid directly to MARKET.live by the brands, retailers, influencers and affiliates referred to MARKET.live by TikTok. In addition, it is contemplated that MARKET.live will receive a percentage of monthly revenue generated through the TikTok stores MARKET.live establishes for the brands, retailers, influencers and affiliates that TikTok Shop refers to MARKET.live.

07:15 EDT Falco Resources confirms admissibility of Horne 5 Project EIA - Falco Resources announced the receipt of confirmation of the admissibility of its Environmental Impact Assessment for the Horne 5 Project located in Rouyn-Noranda from the Ministry of the Environment, the Fight Against Climate Change, Wildlife and Parks. Since the initial EIA filing in 2018, Falco has completed extensive field work and studies, in addition to providing the documentation in order to respond to questions and requests for information raised by the MEFCCWP. Driven by ESG principles, the EIA was conducted by a multidisciplinary team comprised of Falco's employees, experts and partners, and highlights the Horne 5 Project's benefits and impacts on its physical, biological and human environments. The EIA includes various measures to avoid, mitigate or compensate for these impacts, and to enhance the project's overall benefits, in a strong corporate governance environment. The EIA and all related documentation are publicly available on the Environmental Assessment Register of the MEFCCWP. Luc Lessard, President and Chief Executive Officer of Falco noted: "In addition to the recent conclusion of the Operating License and Indemnity Agreement with Glencore Canada Corporation on January 23, 2024, the Horne 5 Project's EIA Admissibility from the MEFCCWP constitutes another significant milestone in advancing closer to the development and realization of the Horne 5 Project. Falco's team has been working extremely hard on the environmental permitting process, and the EIA Admissibility provides the path forward for the advancement of the Project. Although important steps remain, we strongly believe in the Horne 5 Project as a green and world-class polymetallic project that will benefit the surrounding communities. We would like to thank everyone involved at the MEFCCWP for their work and continued assistance throughout this process. Falco would also like to thank the communities of Rouyn-Noranda for their engaged and active participation and continuous support."

07:13 EDT White Gold provides exploration update on Bridget, Isaac targets - White Gold provided an exploration update on the Bridget and Isaac porphyry targets located on the Pedlar and Hayes properties, respectively. Exploration work completed during 2023 included Induced Polarization chargeability and resistivity survey lines and hyperspectral analysis on 2022 prosecting rock samples. All data collected thus far on these large early-stage targets continue to support a porphyry deposit model. The Pedlar and Hayes properties are situated in the southern part of the Company's 315,000 hectare land package in the White Gold District, west-central Yukon. Western Copper and Gold Corporation's Casino copper-gold-molybdenum porphyry deposit (Measured & Indicated Resources of 7.6 Blb copper and 14.5 Moz gold and Inferred Resources of 3.3 Blb copper and 6.6 Moz gold) sits approximately 30 km southwest and 40 km west of the Bridget and Isaac targets respectively. Casino is one of the largest undeveloped copper-gold projects in Canada, and since 2021 has seen strategic investments by major partners including Rio Tinto Canada Inc. and Mitsubishi Materials Corporation. The Pedlar and Hayes properties are also located 40 km and 72 km southeast, respectively, of the Company's flagship White Gold project which contains an estimated 1,152,900 ounces of gold in Indicated Resources and 942,400 ounces of gold in Inferred Resources. Terry Brace, Vice President of Exploration commented: "We are encouraged by results of the 2023 IP test lines at the Bridget and Isaac targets which identified new anomalies and structures that overall correlate well with the soil geochemistry anomalies and current structural interpretations. The new IP looked deeper than any previous geophysical surveys and demonstrates potential at depth beneath these large multi-element soil anomalies. The test results warrant full IP survey coverage over the target areas which will aid in mapping these systems at depth in support of future diamond drill testing."

07:11 EDT EBRD, Erste approve financing for Pupin windfarm in Serbia - Enlight Renewable Energy announced The European Bank for Reconstruction and Development, together with Erste Group Bank AG and its local bank Erste Bank a.d. Novi Sad, have approved a financing package worth $101 million for the construction of a new windfarm in Serbia, which will be built by Enlight. The financing package will provide a major boost to the country's goal of diversifying its energy mix. The EBRD and Erste will provide parallel loans, worth $50.5 million each, including the associated debt service reserve facilities. Enlight's local subsidiary will use the proceeds to develop, construct and operate the 94-megawatt windfarm, which has been originated by Enlight and New Energy Solutions, and named in honour of Mihajlo Pupin, one of Serbia's greatest scientists. The Pupin project is expected to begin operating commercially in the second half of 2025. It is an extension of the existing Kovacica windfarm in Vojvodina, which is also owned by Enlight and was financed by the same lenders in 2017. Once commissioned, the Pupin windfarm will be able to supply clean, green electricity to more than 40,000 households, equivalent to the number of households in a medium-sized city like Zrenjanin. The windfarm will also help to reduce the carbon intensity of Serbia's power sector and advance its green economy transition. Coal still dominates electricity production in Serbia and the financing package comes at a time when the country faces an urgent need to diversify away from fossil fuels to help address its long-term structural energy challenges. This project was financed under Serbia's first renewable energy auction for wind capacity, which took place in 2023 and awarded contract-for-difference for 400 MW. A second and third auction, each for 300 MW of wind capacity, are expected to take place in 2024 and 2025, respectively. Similar auctions will be held in parallel for solar power plants. The scheme was developed and launched with technical and policy support from the EBRD and was funded by the Swiss State Secretariat for Economic Affairs. The scheme encourages the market integration of renewables, as developers receive support in line with market prices, as well as income from the sale of electricity.

07:08 EDT Novocure: METIS Phase 3 clinical trial met primary endpoint in NSCLC study - Novocure announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields TTFields therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer NSCLC following stereotactic radiosurgery SRS . Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis . Median TTFields therapy treatment duration was 16 weeks and median usage was 67%. Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function. Baseline characteristics were well balanced between arms. "Patients with brain metastases from non-small cell lung cancer are frequently treated with radiosurgery but face a high likelihood of rapid brain relapse," said Minesh Mehta, MD, Chief of Radiation Oncology and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida. "In this international, multicenter, phase 3 trial, the use of TTFields therapy significantly delayed time to brain relapse, with associated improvement in quality of life and stable cognition. This is a major benefit and is potentially practice changing." Preliminary analyses of key secondary endpoints did not demonstrate statistical significance. Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life. Full analysis of secondary endpoints is ongoing. "Novocure's willingness to pursue areas of considerable unmet need, like the patient population studied in METIS, is a point of pride for our company," said Asaf Danziger, Novocure's Chief Executive Officer. "We are so pleased with the positive outcome of this trial and encouraged by TTFields' performance. I would like to thank everyone involved with METIS, especially our courageous patients and dedicated investigators, for their contributions to the trial and for meaningfully contributing to the evolution of treatment of brain metastases from NSCLC." Novocure intends to submit these data to regulatory authorities. Novocure also intends to publish these findings in a peer-reviewed scientific journal and share them at an upcoming scientific congress.

07:08 EDT iBio enters collaboration agreement with AstralBio - iBio announces that it has entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio's ability to create antibodies against hard-to-drug targets with AstralBio's significant biologics experience and drug development expertise. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for the treatment of cardiometabolic disease. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta superfamily for the treatment of muscle wasting and obesity.

07:06 EDT Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial - Atea Pharmaceuticals announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. "COVID-19 continues to be a threat, leaving the most vulnerable at risk for severe outcomes from infection. The rapid pace of enrollment recently experienced in the monotherapy cohort of SUNRISE-3 highlights the continuing unmet medical need for new oral COVID-19 treatment options for high-risk patients, such as the elderly, immunocompromised and those with underlying risk factors," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board, the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024 with the goal of moving a step closer to providing a new oral antiviral treatment for people at high risk for COVID-19 progression."

07:03 EDT Ginkgo Bioworks and AQUA Cultured Food announce partnership - AQUA Cultured Foods, a food tech company producing alternative seafood options through the use of microbial fermentation, and Ginkgo Bioworks announced a new partnership. AQUA has chosen Ginkgo to help optimize its innovative fermentation technology to elevate the quality of its fish-free seafood products that authentically replicate the look, feel, and taste of fresh-caught seafood. Leveraging Ginkgo's microbial characterization and analytics, along with AQUA's proprietary strains and processes, the partners aim to transform the future of alt-seafood production. AQUA's fermentation process provides an alternative to fishing and fish farming. Research shows that there are serious health risks associated with eating both wild-caught seafood from the ocean and farmed fish.

06:59 EDT Timken CEO Richard Kyle to retire, Tarak Mehta to succeed - Timken board of directors has reached an agreement with Tarak Mehta to become Timken's next president and chief executive officer on September 5. Mehta is currently president of the Motion business and member of the group executive committee at ABB. Mehta will be appointed Timken president and CEO after he completes a transition period with ABB. Richard Kyle will remain president and CEO until Mehta's appointment date. At that time, Kyle will move into an advisory role to assist with the leadership transition. Kyle plans to retire as an employee of Timken following a decade of leadership as CEO but will continue to serve on the Timken board of directors.

06:55 EDT Spire Global announces agreement with HANCOM InSpace - Spire Global announced an agreement with HANCOM InSpace, initially a spin-off by Korea Aerospace Research Institute and now a part of HANCOM Group, for Sejong-2 and Sejong-3 two additional satellites with Spire Space Services. Under this agreement, Spire will build and operate the satellites, expanding the capabilities of HANCOM-1. Together, these satellites will form a constellation for Korea's first three-satellite remote sensing image data service. Sejong-1, a Spire satellite carrying an optical payload for Hancom, launched in May 2022 on the SpaceX Transporter-5 Mission from Cape Canaveral Space Force Station. It was the first commercial satellite deployed for a private South Korean company.

06:39 EDT Moderna advances multiple vaccine programs to clinical trials - Moderna announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business. The vaccine portfolio seeks to address infectious diseases that Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms. Latent viruses can reactivate and cause clinical symptoms as a person ages, during times of stress or when immunity is compromised. The capacity for latency is a dening feature of members of the Herpesviridae family, including cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, herpes simplex virus, or HSV, and Varicella-Zoster virus, or VZV, cause considerable health burdens and includes 28 vaccines addressing respiratory, latent and other pathogens.

06:36 EDT Dr. Reddy's enters partnership with Sanofi to distribute vaccines in India - Dr. Reddy's Laboratories (RDY) announced that it has entered into an exclusive partnership with Sanofi Healthcare India (SNY) to promote and distribute Sanofi's vaccine brands across private markets in India. Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's pediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim. Sanofi will continue to own, manufacture, and import these brands to the country.

06:25 EDT AstraZeneca, Sanofi announce Beyfortus approved in Japan - AstraZeneca (AZN) and Sanofi's (SNY) Beyfortus, a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV, in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season. Beyfortus is anticipated to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines. Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: "The approval of Beyfortus means it is possible for the first time to prevent serious respiratory disease due to RSV for all infants in Japan and reduce the infectious disease burden on healthcare systems. Beyfortus reflects AstraZeneca's commitment to the scientific development of preventive options to support the most vulnerable patient populations and we look forward to making Beyfortus available in Japan for the 2024/25 season."

06:16 EDT Infosys announces strategic collaboration with Handelsblatt Media Group - Infosys announced a strategic collaboration with the Handelsblatt Media Group, a media company for business and financial information in Germany. As an AI and digital innovation partner for the Handelsblatt Media Group, Infosys will bring the best of digital technology to power innovative storytelling to inform and delight Handelsblatt's core audience. In the first year of this partnership, Infosys will work with Handelsblatt Research Institute, or HRI, an independent economic research institute under the umbrella of the Handelsblatt Media Group. Infosys will leverage Infosys Topaz, an AI-first set of services, solutions and platforms using generative AI technologies, to support the HRI in making complex HRI reports on global economic and financial topics more accessible and consumable for the public. In the first year of this partnership, Infosys will work with Handelsblatt Research Institute, or HRI, an independent economic research institute under the umbrella of the Handelsblatt Media Group. Infosys will leverage Infosys Topaz, an AI-first set of services, solutions and platforms using generative AI technologies, to support the HRI in making complex HRI reports on global economic and financial topics more accessible and consumable for the public.

06:04 EDT Hywin Holdings announces business transformation plan and headcount reduction - Hywin Holdings announced its plan for strategic business transformation in light of recent regulatory policies and market developments. Under this new strategy, the Company will shift its financial services and product distribution businesses towards public market funds and NAV-based products, strategically promote growth of its insurance brokerage services business, continue to grow and develop its overseas wealth management and asset management services, and diversify income streams by continuing to develop other non-financial service businesses such as high-end health management services, and opportunistically expanding into consumer industries including distribution of Chinese liquors and other consumer products, which Hywin expects may achieve potential synergy with its existing clientele of high-net-worth individuals in China. Against the backdrop of adverse market conditions, and the challenging liquidity environment in which it operates, Hywin has ceased to distribute asset-backed products, and will shift its business focus from fixed-income wealth management products to NAV-based products and insurance brokerage services. Hywin has investigated reports of defaults of asset-backed products it had historically distributed and is actively addressing these redemption issues, while proactively coordinating with asset managers, relationship managers and clients to seek solutions and reduce client losses. As part of the business transformation plan, Hywin is undertaking a structural reorganization plan, which includes elimination of certain positions and aggressive cost saving measures, including the redundancy of approximately 300 middle- and back-office employees. Further redundancy of frontline employees may occur as Hywin is in the process of setting up new sales policies and targets for its nationwide relationship manager team.

05:32 EDT Nio cuts Q1 delivery view to 30,000 vehicles from 31,000-33,000 vehicles - Nio provided an updated delivery outlook for the first quarter of 2024. Based on the most recent business update, the Company expects to deliver approximately 30,000 vehicles in the first quarter of 2024, revised from the previous outlook of 31,000 to 33,000 vehicles.

05:21 EDT Argenx advances clinical development of efgartigimod - Argenx announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease, or SjD, following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting. The decision to advance the clinical development of efgartigimod in SjD was supported by the safety, efficacy and biomarker results from the study. The observed safety and tolerability profile was consistent with other clinical trials. Efficacy assessments showed a treatment effect across multiple clinical endpoints, which were also consistent with biomarker data.

05:15 EDT Waterdrop declares 4c per share special cash dividend - Waterdrop declared a special cash dividend, the aggregate payment of which amounted to approximately $15M. The special cash dividend of 4c per ADS or $0.004 per ordinary share for 2023 to shareholders of record as of the close of business on April 19. The payment date is expected to be on or around April 30 for holders of ordinary shares and on or around May 3 for holders of ADSs.

05:06 EDT Viomi Technology receives noncompliance notification from Nasdaq - Viomi Technology announced that it has received a written notification from the staff of Nasdaq dated March 26, indicating that because the closing bid price of the company's ADSs for the last 30 consecutive business days was below $1.00 per share, the company no longer meets the Nasdaq minimum bid price requirement, set forth in Nasdaq Listing Rule 5450.